ESR1 and breast cancer: Further dose titration experiments showed that the combination of the selective ER downregulators (SERDs), such as fulvestrant and elacestrant, with the KAT6 inhibitor contributed to synergistic effects in MCF7 and T47D breast cancer cells, increasing their sensitivity to ET.